BofA/Merrill Lynch Upgrades Amylin Pharmaceuticals (AMLN) to Neutral
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 20
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 20
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Amylin Pharmaceuticals (NASDAQ: AMLN) from Underperform to Neutral. PT increased from $11 to $16.
For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $13.71 yesterday.
For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $13.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Keefe, Bruyette & Woods Upgrades Nayax (NYAX) to Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
